in KYOTO
The Joint Meeting of

The 12th World Congress of International Society for Apheresis

ISFA2019
JSFA2019

The 40th Annual Meeting of Japanese Society for Apheresis

Program & Abstracts

Date : October17(Thu)-20(Sun), 2019

Venue : Kyoto International Conference Center, Kyoto, Japan
Congress President : Yoshihiro Endo, MD, PhD

Professor, Department of Clinical Nursin
Nursing , Shiga University of Medical Science
President, ISFA

in KYOTO

Dear Friends and Colleagues,
I am pleased to welcome you to the 12th World Congress of International Society for Apheresis(ISFA), in conjunction with the 40th Annual Meeting of Japanese Society for Apheresis ( JSFA),
which will take place in Kyoto, Japan October 17th - 20th in 2019.
ISFA is the unique international society for apheresis mainly composed of individual members. It
was founded in 1996 to disseminate the most up-to-date apheresis technologies and their clinicalapplications. Almost 500 members from all over the world have joined us today.
ISFA’s congress is to be held biennially, and the venue is to be arranged in the region of America,
Europe, or Pan-Pacific in rotation. This will be the second ISFA congress held in Kyoto, following
the 1st World Congress of ISFA in 1996. It is my profound pleasure and great honor to host ISFA
2019 back again in Kyoto, which reminds us the memorable 1st ISFA Congress.
JSFA had originally started as Japanese Society for Therapeutic Plasmapheresis (the predecessor of
JSFA) in 1982. JSFA was established based on it in 1992, and it has evolved into a big society withmore than 1,600 members ever since.
Being held at the same time, ISFA 2019 & JSFA 2019 must become a historic meeting. This
congress will serve as a springboard again and strongly contribute the remarkable and world-wide
advancement of apheresis in both scientific and clinical fields.
You can participate in very active discussions and cutting edge lectures by the world-famousscientists, physician, clinical engineers and nurses. Or you can just look to see how otherprofessionals deal with the clinical cases of apheresis. This congress promises to become a useful
opportunity for you to encounter the up-to-date technologies of apheresis.
Kyoto is famous for wonderful historic scenery with traditional architecture and beautiful natureof more than 1200 years. It has 17 UNESCO World Cultural Heritage Sites and over 2,000
temples and shrines.
Many of the tourist cities are easily accessible from Kyoto, because it is located at the main traffic
point and at the geographic center of Japan. You can get any places in Japan by trains or aircrafts
within a couple of hours.
I am very excited to see you from every part of the world and to welcome you to FANTASTIC
KYOTO.
Sincerely,

Yoshihiro Endo, MD, PhD.

Congress PresidentInternational Society for Apheresis (ISFA)
Japanese Society for Apheresis ( JSFA)
3

ISFA & JSFA 2019 in KYOTO
Oct 18th Room A

9:00-10:30

Workshop

E-ISFA Workshop Kyoto
Chairs: Bernd Hohenstein
Wolfgang Ramlow

WS-01

Update on vasculitis treatment including plasma exchange
Wladimir Szpirt

WS-02(Rigshospitale, Copenhagen, Denmark)

Lipoprotein(a): Delicate Risk Factor and Prime Target for Apheresis
Wolfgang Ramlow

WS-03(Nephrological Center Villingen-Schwenningen, Germany)(Apheresis Center Rostock, Germany)(Apheresis Center Rostock, Germany)

Why should immunoadsorption be a therapy of continuing interest?
Bernd Hohenstein

10:45-12:15(Nephrological Center Villingen-Schwenningen, Germany)

Symposium 1

Current State of CAR-T Therapies in the World
Chair:

Chisa Yamada(Department of Pathology, University of Michigan, USA)SY1-01 Current Status of CAR-T Therapy in the United States
Nicole Aqui

(Department of Pathology and Laboratory Medicine, University of Pennsylvania,
Philadelphia, Pennsylvania, USA)SY1-03 Basic and clinical studies of CAR-T cell therapy in Japan
Keiya Ozawa

12:30-13:30(Division of Immuno-Gene & Cell Therapy (Takara Bio), Jichi Medical University,
Tochigi, Japan)

Luncheon Seminar 1
Sponsored by Novartis Pharma K.K.

Standard of Apheresis/Cell processing Site for CAR-T therapy
Chair:

LS1-01

Peter Holman

Institutional preparation for CAR-T Cell Therapy and Apheresis
Peter Holman

LS1-02(Global Apheresis Integration, Novartis Pharmaceuticals Corp., Germany)

How to establish the management system for CAR-T therapy in Japan
Masafumi Onodera

12(Global Apheresis Integration, Novartis Pharmaceuticals Corp.,
Germany)(Gene and Cell Therapy Promotion Center, National Center for Child Health andDevelopment)Remembrance of Dr. Akira Yamamoto

Special Lecture

SL1-01

Mariko Harada-Shiba (Molecular Innovation in Lipidology, National Cerebral and CardiovascularCenter Research Institute, Japan)

In Memory of Prof. Akira Yamamoto

15:30-17:00(Department of Clinical Nursing, Shiga University of Medical Science, Japan)

Symposium

Yoshihiro Endo

Symposium 2

Guideline
SessionSL1-02

Registry of lipoprotein apheresis

Apheresis
Manual Lecture

Chairs: Patrick M. Moriarty(University of Kansas Medical Center, USA)
Mariko Harada-Shiba (Molecular Innovation in Lipidology,National Cerebral andCardiovascular Center Research Institute, Japan)

Patrick M. Moriarty

Technical Talk

SY2-01 North American Lipoprotein Apheresis Registry (NALAR): Data collection
design and rationale(University of Kansas Medical Center, USA)

E-ISFA
Work Shop

SY2-02 Registry of homozygous familial hypercholesterolemia
Mariko Harada-Shiba (Molecular Innovation in Lipidology, National Cerebral and CardiovascularCenter Research Institute, Japan)

SY2-03 Current insights into the German Lipoprotein Apheresis Registry (GLAR), morethan 7 years on
Volker J. J. Schettler(Center of Nephrology Goettingen GbR, Goettingen, Germany)

SY2-04 LDL apheresis in Heterozygous Familial Hypercholesterolemia : data from the
French Registry of Familial hypercholesterolemia (REFERCHOL)
Antonio Gallo

17:05-18:05(Cardiovascular Prevention Unit, University Hospital Pitie Salpetriere, France)

Evening Seminar 1
Sponsored by AbbVie

ES1-01

Taku Kobayashi(Center for Advanced IBD Research and Treatment,
Kitasato University Kitasato Institute Hospital, Tokyo, Japan)

Sponsored
Seminar

Chair:

PosterPresentation

Treatment of inflammatory bowel disease in Europe

Treatment of inﬂammatory bowel disease in Europe
Rodolfo Sacco

State of the Art
in the World

Tadao Akizawa(Neurology, National Hospital Organization, Nagasaki National Hospital,
Japan)(Division of Nephrology, Department of Medicine, Showa University
School of Medicine, Japan)

EnglishOral Session

Chairs: Hidenori Matsuo

ProgramSaturday, Oct.
19, 2019

Memorial Seminar for the late Prof. Akira Yamamoto

ProgramSunday, Oct.
20, 2019

Special Lecture 1

Japanese
Oral Session

14:30-15:00

ProgramFriday, Oct.
18, 2019

Program & Abstracts(Gastroenterology and Digestive Endoscopy Unit, University of Foggia Medical
School, Italy)

13

ISFA & JSFA 2019 in KYOTO

18:10-18:40

Special Lecture 2

Commemorating Seminar, JSFA to be the member society of the Japanese
Association of Medical Science
Chairs: Hiroshi Tsuda
Hidenori Matsuo

SL2-01SL2-02

Tetsuzo Agishi
Michio Mineshima(Center for Advanced IBD Research and Treatment, Kitasato
University Kitasato Institute Hospital, Tokyo, Japan)(Neurology, National Hospital Organization, Nagasaki National Hospital, Japan)(Professor emeritus, Tokyo Women’s University, Japan)(Department of Clinical Engineering, Tokyo Women’s Medical University, Tokyo, Japan)

Room D

9:00-10:35

Symposium 3 _ IBD 1

Apheresis therapy for inflammatory bowel disease -Past, Present, Future-1
Chairs: Yamin Lai
Makoto Naganuma(Peking Union Medical College Hospital (Dongdan campus), No.1
Shuaifuyuan Wangfujing Dongcheng District, Beijing,China)(Division of Gastroenterology and Hepatology, Keio University Schoolof Medicine, Japan)

SY3-01 Leukocytapheresis as an Adjunct to Medication for Inﬂammatory Bowel Disease
Koji Sawada(Directer of Dojima General & Gastroenterology Clinic, Japan)

SY3-02 Granulomonocytoapheresis as therapeutic option of IBD in Europe
Rodolfo Sacco(Gastroenterology and Digestive Endoscopy Unit, University of Foggia Medical School, Italy)

SY3-03 Adsorptive Granulocyte and Monocyte Apheresis in the Treatment ofInﬂammatory Bowel disease : The First Multicenter Study In China
Yamin Lai

(Peking Union Medical College Hospital (Dongdan campus), No.1 Shuaifuyuan
Wangfujing Dongcheng District, Beijing,China)

SY3-04 Real-world experiences of cytapheresis therapy for ulcerative colitis; resultsfrom large-scale multicenter observational studies
Taku Kobayashi(Center for Advanced IBD Research and Treatment, Kitasato University Kitasato
Institute Hospital, Tokyo, Japan)

SY3-05 Factors affecting clinical remission in patients with ulcerative colitis treated withcytapheresis therapy
Shigeki Bamba

10:45-12:15(Division of Clinical Nutrition, Shiga University of Medical Science, Japan)

Symposium 4 _ IBD 2Apheresis therapy for inflammatory bowel disease -Past, Present, Future-2
Chairs: Yamin Lai
Makoto Naganuma(Peking Union Medical College Hospital (Dongdan campus), No.1
Shuaifuyuan Wangfujing Dongcheng District, Beijing,China)(Division of Gastroenterology and Hepatology, Keio University Schoolof Medicine, Japan)

SY4-01 A novel leucoyte apheresis adsorption system in refractory active ulcerative colitis
Wolfgang Kruis

14(Evangelisches Krankenhaus Köln Kalk ( Formerly active as chief physician ), Germany)

SY4-03 The efﬁcacy of combination therapy of intensive GMA with biologics or a JAK
inhibitor for refractory inﬂammatory bowel disease(Department of Gastroenterology and Metabolism, Japan)

SY4-04 Efﬁcacy apheresis as maintenance therapy for patients with ulcerative colitis in aprospective multicentre randomised controlled trial

Special Lecture

Sponsored by JIMRO

Vascular access practices for GMA treatment

Guideline
SessionVascular Punctures for GMA treatment
Hisashi Matono

LS2-02(Department of Internal Medicine and Rheumatology, Juntendo
University School of Medicine, Japan)(Department of medical engineer, Wakakusa-Daiichi Hospital, Japan)

Tips for ensuring vascular access and maintaining extracorporeal circulation inpediatric blood puriﬁcation therapy
Mariko Sawada

15:30-17:00(Department of Pediatrics, Kurashiki Central Hospital, Japan)

Symposium 5 _ Dermatology

E-ISFA
Work Shop

LS2-01Ken Yamaji

Advancement of Apheresis in Dermatology
Chairs: Chisa Yamada
Shigaku Ikeda(Transfusion Medicine, Department of Pathology, University ofMichigan, Ann Arbor, Michigan, USA)
(Department of Dermatology, Juntendo University School of Medicine,Japan)

SY5-01 Granulocyte and monocyte adsorption apheresis for generalized pustular
psoriasis
Mariko Seishima(Department of Dermatology, Gifu University Graduate School of Medicine, Japan)

SY5-02 Granulocyte and monocyte adsorption apheresis for psoriatic arthritis(Department of Dermatology, Kagoshima University, Kagoshima, Japan)

PosterPresentation

Takuro Kanekura

SY5-03 Extracorporeal Photopheresis Treatment for Dermatological Diseases(Transfusion Medicine, Department of Pathology, University of Michigan,
Ann Arbor, Michigan, USA)

Sponsored
SeminarChisa Yamada

SY5-04 Autologous Hematopoietic Stem Cell Transplantation for Treatment of Severe
Systemic Sclerosis
Mark Wener

Apheresis
Manual Lecture

Chair:

Symposium

Luncheon Seminar 2

Technical Talk

12:30-13:30(Division of Gastroenterology and Hepatology, Keio University School of
Medicine, Japan)

State of the Art
in the World

Makoto Naganuma

EnglishOral Session

Satoshi Tanida

ProgramSaturday, Oct.
19, 2019(Division of Gastroenterology Department of Medicine, Kurume University Schoolof Medicine, Kurume, Japan)

Japanese
Oral Session

Youichiro Shindo

ProgramSunday, Oct.
20, 2019

SY4-02 Safety and efﬁcacy of single needle leucocyte apheresis for ulcerative colitis: A
retrospective analysis

ProgramFriday, Oct.
18, 2019

Program & Abstracts(University of Washington, Department of Laboratory Medicine & Division ofRheumatology, USA)

15

ISFA & JSFA 2019 in KYOTO

17:05-18:05

Evening Seminar 2
Sponsored by Asahi KASEI Medical

Latest findings of cell-free and concentrated ascites reinfusion therapy (CART)
using blood purification equipment “Plasauto μ”
Chair:

ES2-01

Motoki Yonekawa

How to handle CART mode on blood puriﬁcation equipment “Plasauto μ”

Hiroyuki Miyakawa

ES2-02(Sapporo Hokuyu Hospital, Japan)(Japanese Red Cross Medical Center, Japan)

Comparison between the internal and external pressure ﬁltration method ofcell-free and concentrated ascites reinfusion therapy and Plasauto μ usability
Midori Hasegawa(Fujita Health University, Japan)

Room B-1

9:00-10:30

Symposium 6 _ PDF SESSION I

Chairs: Alexey A. Sokolov
Yutaka Eguchi(The Department of Anesthesiology and Reanimatology,
North-Western State Medical University named after I.I.Mechnikov,
St.Petersburg, Russia)(Department of Critical and Intensive Care Medicine, Shiga Universityof Medical Science, Japan)

SY6-01 The improvement of acute kidney injury by plasmadiaﬁltration on sepsis animal
model
You Li(Dept. of Nephrology, Huashan Hospital, Fudan University, Shanghai, China)

SY6-02 Plasma adiponectin levels in acute liver failure patients treated with plasma
ﬁltration with dialysis and plasma exchangead
Yoshitaka Uji(Department of Emergency and Gastroenterological Surgery, Shin-Koga Hospital,
Fukuoka, Japan)

SY6-03 PDF procedure induce IL-10; a case report
Yutaka Eguchi(Department of Critical and Intensive Care Medicine, Shiga University of Medical
Science, Japan)

SY6-04 Utility of the novel artiﬁcial liver support combination therapy, PDF with highﬂow-volume CHDF
Kota Kamizato(Department of Anesthesiology and Intensive Care Medicine, University of the
Ryukyus, Okinawa, Japan)

SY6-05 High ﬂow-volume plasma ﬁltration with dialysis and plasma exchange withdialysis
Hajime Nakae(Department of Emergency and Critical Care Medicine, Akita University Graduate
School of Medicine, Japan)

SY6-06 Continuous plasmaﬁltration with dialysis (CPDF)
Takumi Taniguchi

16(Department of Anesthesiology and Intensive Care Medicine, Kanazawa
University, Kanazawa, Japan)

Program & Abstracts

ProgramSaturday, Oct.
19, 2019
ProgramSunday, Oct.
20, 2019

SY7-01 Comparison of selective plasma exchange, plasma diaﬁltration, MARS and
Prometheus systems in treatment of liver failure(Blood Purification Center, Osaka Medical College, Japan)

Hironori Hayashi(Department of Surgery, Toyama Prefectural Central Hospital, Japan)

SY7-04 Multicenter Study of Plasma ﬁltration with dialysis (PDF) in Patients with AcuteLiver Failure
Yutaka Eguchi(Department of Critical and Intensive Care Medicine, Shiga University of Medical
Science, Japan)

SY7-05 Clinical application and effect analysis of plasma diaﬁltration (PDF) in patientswith liver failure
Yi Tian

12:30-13:30(Dep.Infectious disease, the Second Xiangya Hospital, Central South University,
Changsha, China)

Luncheon Seminar 3
Sponsored by NIKKISO

Adsorption mechanism of Immunopure
Grit Waitz(Nephrocare Rostock GmbH Medizinisches Versorgungszentrum Südstadt,
Germany)

Grit Waitz(Nephrocare Rostock GmbH Medizinisches Versorgungszentrum
Südstadt, Germany)

Apheresis for treatment of active ulcerative colitis: evidence and developments
Wolfgang Kruis

16:00-17:00
AM-01

EnglishOral Session

Chair:

LS3-02(The hospital Evangelisches Krankenhaus Köln Kalk, Germany)(The hospital Evangelisches Krankenhaus Köln Kalk, Germany)

Apheresis Manual Lecture

Sponsored
Seminar

LS3-01

Wolfgang Kruis

State of the Art
in the World

Chair:

Guideline
SessionMaki Kagitani

SY7-03 Artiﬁcial liver support for liver transplant recipients during perioperative period

Apheresis
Manual Lecture

SY7-02 Safety Management in Plasma Diaﬁltration

Symposium

Special Lecture(The Department of Anesthesiology and Reanimatology, North-Western State
Medical University named after I.I.Mechnikov, St.Petersburg, Russia)

Technical Talk

Alexey A. Sokolov

E-ISFA
Work Shop

Hajime Nakae(Dept. of Nephrology, Huashan Hospital, Fudan University,
Shanghai, China)(Department of Emergency and Critical Care Medicine, Akita
University Graduate School of Medicine, Japan)

Japanese
Oral Session

Chairs: Xue Jun

ProgramFriday, Oct.
18, 2019

Symposium 7 _ PDF Session II

PosterPresentation

10:45- 12:00

Acute blood puriﬁcation therapy in critical care
Takahisa Tabata

17

ISFA & JSFA 2019 in KYOTO
Room B-2

9:00-10:30
Chair:

State of the Art 1 _ Critical Care Medicine

Paul S. Malchesky(ICAOT, USA)SA1-01 Current status of plasma exchange in critical ill patients in Vietnam
Hien_Thi Thu Huynh (Cho Ray Hospital, Ho Chi Minh, Vietnam)

SA1-03 Results from the CAMI1 Study: Selective CRP apheresis as a new treatment
option in acute myocardial infarction
Ahmed Sheriff(Charite Universitaetsmedizin, Medizinische Klinik Gastroenterologie/
Infektiologie/ Rheumatologie, Germany)

SA1-04 The improving effects of lipoprotein apheresis on cardiac vascular ultrasonicparameters
Dongliang Zhang(The Blood Purification Center of Nephrology Department, Peking University
International Hospital, China)

SA1-05 After EUPHRATIS Is LPS Apheresis for Sepsis obsolete? In-vitro investigation
for a new concept of Endotoxin adsorption
Mandry Peter

10:45-12:15
Chair:(B. Braun Avitum Saxonia GmbH, Germany)

State of the Art 2 _ Nephrology/Others

Dusit Lumlertgul(Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand)SA2-01 Severe Nephrotic Syndrome with Hyperthyroidism and Acute Renal Failure
Treatment with Plasmapheresis and Immunosuppressive drug: Tacrolimus
Dusit Lumlertgul(Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand)SA2-02 Effects of LDL-Apheresis in Adult Refractory Nephrotic Syndrome and Its
Reproducibility
Hideki Takizawa(The Department of Nephrology, Teine Keijinkai Hospital, Sapporo, Japan)

SA2-03 Plasmapheresis Reduces Mycophenolic Acid Concentration: A Study of Full AUC0-12
Sudarat Piyasiridej(Nephrology unit, Department of Medicine, Chulalongorn University, Bangkok, Thailand)SA2-04 Immunoadsorption treatment of recurrent primary focal segmental
glomerulosclerosis: A single center experience
Hamza Naciri Bennani (Department of Nephrology, Hemodialysis, Apheresis and Renal Transplantation,
CHU Grenoble-Alpes, Grenoble, France)

SA2-05 Apheresis therapy for steroid-resistant idiopathic nephrotic syndrome: Reporton three cases
Hamza Naciri Bennani (Department of Nephrology, Hemodialysis, Apheresis and Renal Transplantation,
CHU Grenoble-Alpes, Grenoble, France)

SA2-06 Rationale and Study Design of LDL apheresis-mediated Endothelial activation
Therapy to Severe-Peripheral Artery Disease study (LETS-PAD study)
Eiko Ueda

18(Department of Medical Science and Cardiorenal Medicine, Yokohama City
University Graduate School of Medicine, Kanagawa, Japan)

Program & Abstracts
ProgramFriday, Oct.
18, 2019
ProgramSaturday, Oct.
19, 2019(Department of Emergency and Critical Care Medicine, Akita
University, Japan)(Department of Anesthesiology & Critical Care Medicine, Fujita Health
University, Toyoake, Japan)

Tomoyuki Nakamura

Special Lecture

EO1-02 The mechanism of the decrease in cardiac output measurement bytranspulmonary thermodilution has been elucidated(Department of Anesthesiology and Critical Care Medicine, Fujita Health
University School of Medicine, Toyoake, Japan)

EO1-03 Treatment of chronic Heavy Metal Intoxication by Plasmapheresis, Promise or
Illusion?
Gerhard Puetz(Institute of Clinical Chemistry and Laboratory Medicine, Faculty of Medicine,
University of Freiburg, Freiburg, Germany)

EO1-04 A Case series -Use of Therapeutic Plasma Exchange (TPE) in the management ofPatients with Snake bite
Indika de Alwis(Regional Blood Centre, T H Ratnapura, Sri Lanka)

EO1-05 Biocompatibility and efﬁcacy of self-anticoagulative chitosan-κ-carrageenan
composite hydrogel for simultaneous endotoxin adsorption and bacteria capture
in septic blood
Yupei Li

(Department of Nephrology, West China Hospital, Sichuan University, Chengdu,
China)(Department of Nephrology, National Hospital Organization, Osaka National
Hospital, Osaka, Japan)

State of the Art
in the World

Masafumi Yamato

E-ISFA
Work Shop

EO1-06 Lactate predicts the 28-day survival rate in patients with septic shock treatedwith the combination of PMX-DHP and rTM

Room E

Yuji Kamijo

EnglishOral Session

Chair:

Japanese Oral 1 _ Ascites/CART(Shinshu University School of Medicine, Japan)

Japanese
Oral Session

9:00-10:00

Symposium

Naohide Kuriyama

ProgramSunday, Oct.
20, 2019

EO1-01 Nafamostat mesylate inhibition of LZD metabolism via its antioxidant effects

Guideline
SessionHajime Nakae

Apheresis
Manual Lecture

Chair:English Oral 1 _ Critical Care Medicine

Technical Talk

15:30-17:00

JO1-01 Investigation of washing volume for Back-ﬁltration cleaning in CART

PosterPresentation

JO1-02 Examination of the optimal ascites concentration rate when using blood
puriﬁcation equipment “Plasauto μ CART mode”
JO1-03 Evaluation of the dedicated equipment, Plasauto μ, for CART (Cell-free andConcentrated Ascites Reinfusion Therapy)

Sponsored
Seminar

JO1-04 Evaluation of safety in CART using blood puriﬁcation equipment Plasauto μ

19

ISFA & JSFA 2019 in KYOTO

10:45-12:15
Chair:

State of the Art 3 _ LDLMariko Harada-Shiba (Molecular Innovation in Lipidology, National Cerebral andCardiovascular Center Research Institute, Japan)

SA3-02 Establishing Low-Density Lipoprotein Apharesis Tolerability in Patients with
Prior Anaphylactoid Reactions to Lipid Apharesis using Magnesium Sulfate
Ethan Alexander(University of Kansas School of Medicine, Department of Clinical Pharmacology,
Kansas City, Kansas, USA)

SA3-03 Impact of PCSK9 inhibitors on LDL apheresis
Samir Saheb(Departement of Endocrinology and Metabolism, Sorbonne University, Paris, France)

SA3-04 Beyond cholesterol, pleotropic effects of lipoprotein apheresis
Volker J.J. Schettler(Center of Nephrology Goettingen, Goettingen, Germany)

SA3-05 Apheresis in preeclampsia – Lipids, angiogenetic factors or else?
(The APPROVE project, a controlled multi-center apheresis trial)
Karl Winkler

15:30-16:00
Chair:(Institute of Clinical Chemistry and Laboratory Medicine, Faculty of Medicine,
University of Freiburg, Germany)

Japanese Oral 2 _ IBD

Yoko Yokoyama(Department of Inflammatory Bowel Disease, Division of Internal
Medicine, Hyogo College of Medicine, Japan)

JO2-01 Effect of cellulose acetate beads on the release of interleukin-13 at different
temperatures
JO2-02 Examination of the therapeutic effect in our hospital GMA LCAP (CAP) therapy
Room D Foyer

10:30-11:50
Chair:

PP1-04

Poster Presentation 1 _ Hepatology/others

Kazuaki Inoue

Fructus Psoraleae-induced severe liver injury and treatment with two artiﬁcial
liver support systems: A case series study
Zhongyang Xie

15:00-16:10
Chair:

PP2-01(State Key Laboratory for Diagnosis and Treatment of Infectious Diseases,
The First Affiliated Hospital, College of Medicine, Zhejiang University, China)

Poster Presentation 2 _ Ascites/CART/IBD

Yuji Kamijo(Shinshu University School of Medicine, Japan)

Biochemical Evaluation of Processed Ascites in Patients Undergoing Cell-Free
and Concentrated Ascites Reinfusion Therapy
Hironori Nakamura

20(Gastroenterology,Showa University Fujigaoka Hospital, Japan)(Department of Nephrology, Shinonoi General Hospital, Nagano, Japan)

Program & Abstracts
Suppression of inﬂammation during cell-free concentrated ascites reinfusion
therapy (CART) using a blood puriﬁcation device

PP2-03

The washing using the normal saline to drain to the two directions for the
clogged ﬁltration ﬁlter is effective

PP2-04Development and clinical evaluation of an ascites ﬁltration and concentrationequipment by interprofessional collaboration

PP2-05

Clinical factors associated with relapse of ulcerative colitis after granulocytemonocyte adsorption

PP2-06

Efﬁcacy and safety of granulocyte and monocyte adsorptive apheresis in elderly
vs. non-elderly patients with ulcerative colitis

PP2-07Development of a tube holder-type circuit set for cell free and concentrated
ascites reinfusion therapy (CART)

Sponsored
Seminar

PosterPresentation

Japanese
Oral Session

EnglishOral Session

State of the Art
in the World

E-ISFA
Work Shop

Technical Talk

Apheresis
Manual Lecture

Guideline
SessionSymposium

Special Lecture

ProgramSunday, Oct.
20, 2019

ProgramSaturday, Oct.
19, 2019

ProgramFriday, Oct.
18, 2019

PP2-0221

PosterPresentation

Japanese
Oral Session

EnglishOral Session

State of the Art
in the World

E-ISFA
Work Shop

Technical Talk

Apheresis
Manual Lecture

Guideline
SessionSaturday, October 19, 2019

Sponsored
Seminar

Symposium

ProgramSpecial Lecture

ProgramSunday, Oct.
20, 2019

ProgramSaturday, Oct.
19, 2019

ProgramFriday, Oct.
18, 2019

ISFA & JSFA 2019 in KYOTO
Oct 19th Room A

9:00-10:30

Symposium 8 _ Critical Care Medicine

Chairs: Xiuming Xi
Takeshi Moriguchi(Past President of CSCCM, China)(Department of Emergency and Critical Care Medicine, University of
Yamanashi School of Medicine, Yamanashi, Japan)

SY8-01 Dose of CRRT in AKI: The Other Way AroundBin Du(Medical ICU, Peking Union Medical College Hospital, China)

SY8-02 Apheresis for Sepsis
Takeshi Moriguchi(Department of Emergency and Critical Care Medicine, University of Yamanashi
School of Medicine, Yamanashi, Japan)

SY8-03 The application of the column adsorbing LAP positive cells to therapy ofsepsis-induced immune paralysis
Kazuo Teramoto(Department of Pathology, Shiga University of Medical Science, Japan)

SY8-04 Early Prediction of Acute Kidney Injury in ICU
Haibo Qiu

10:45-12:15(Dept. of Critical Care Medicine, Zhongda Hospital, School of Medicine, Southeast
University, China)

Symposium 9 _ PMX

Update report, PMX on sepsis
Chairs: Tohru Tani

(Department of Research and Development for Innovative Medical
Devices and Systems, Shiga University of Medical Science, Japan)(Toray Medical Co., Japan)

Hisataka Shoji

SY9-01 Impact of timing of polymyxin B immobilized ﬁber column direct hemoperfusion
on outcome in patients with septic shock
Tomoki Tanaka(Shiga University of Medical Science Emergency and Intensive Care Unit, Shiga, Japan)

SY9-02 Blood puriﬁcation for septic shock patients
Toshiaki Ikeda(Division of Critical Care Medicine Tokyo Medical University, Hachioji Medical
Center, Japan)

SY9-03 Role of Rescue therapy using Polymyxin B Hemoperfusion in
immunocompromised hosts with refractory septic shock
Sang-Bum Hong

(Department of Pulmonary and Critical Care Medicine, Asan Medical Center inSeoul, Univ. of Ulsan, College of Medicine, Korea)

SY9-04 The case for using PMX in critically ill patients – Don’t through out the baby
with the bath water
Sean M. Bagshaw

12:30-13:30(Critical Care Medicine, University of Alberta, Canada)

Luncheon Seminar 4*Simultaneous interpretation is available.

Sponsored by Asahi KASEI Medical

Pathogenic Antibodies and Lipoproteins – Current Trends in Therapeutic
Apheresis
Chair:

24

Hidenori Matsuo(National Hospital Organization, Nagasaki National Hospital, Japan)

GS1-01 The JSFA clinical practice guideline for Therapeutic Apheresis(Department of Urology, Iwate Medical University, Iwate, Japan)

Norio Hanafusa

Symposium

GS1-02 The Chapter for the Kidney Diseases, the Japanese Society for Apheresis
Guideline(Department of Blood Purification, Tokyo Women’s Medical University, Tokyo, Japan)

GS1-03 Clinical practice guidelines for therapeutic apheresis in emergency and criticalcare
Hajime Nakae(Department of Emergency and Critical Care Medicine, Akita University Graduate
School of Medicine, Japan)

GS1-04 The apheresis guidelines for digestive diseases
Kazuaki Inoue
Tomoki Furuya
Yoko Yokoyama(Division of Gastroenterology, Department of Internal Medicine, Showa University
Fujigaoka Hospital, Yokohama, Japan)(Department of Emergency and Critical Care Medicine, Akita University Graduate
School of Medicine, Japan)(Department of Internal Medicine, Division of Inflammatory Bowel Disease,
Hyogo College of Medicine, Japan)

GS1-05 Guideline of Apheresis in Cardiovascular Disease
Mariko Harada-Shiba (National Cerebral and Cardiovascular Center Research Institute, Japan)

Shinji Abe(Department of Respiratory Medicine, Tokyo Medical University, Japan)

EnglishOral Session

15:30-17:00

State of the Art
in the World

GS1-06 Guidelines on the use of therapeutic apheresis in pulmonary diseases:
the potential treatment with direct hemoperfusion with polymyxin
B-immobilized ﬁber column (PMX-DHP) for diffuse alveolar damage (DAD)

Guideline Session 2

Chairs: Hidenori Matsuo(National Hospital Organization, Nagasaki National Hospital, Japan)

GS2-01 Standardization of apheresis technologies
Michio Mineshima(Department of Clinical Engineering, Tokyo Women’s Medical University, Tokyo, Japan)

Sponsored
SeminarGS2-02 Apheresis guideline in Japan for management and treatment of pemphigus,
bullous pemphigoid and toxic epidermal necrolysis
Mariko Seishima(Department of Dermatology, Gifu University Graduate School of Medicine,Japan)

GS2-03 Japanese apheresis guidelines for the management and treatment of generalized
pustular psoriasis, pustulosis palmoplantaris and psoriasis arthropathica
Miho Hatanaka

Guideline
SessionTakaya Abe

ProgramSaturday, Oct.
19, 2019
Special Lecture(National Hospital Organization, Nagasaki National Hospital, Japan)

Apheresis
Manual Lecture

Hidenori Matsuo

Technical Talk

Chair:

Guideline Session 1

E-ISFA
Work Shop

13:40-15:30(Apheresis Research Institute, Cologne and 1st Department of Internal Medicine,
University of Mainz, Germany)

Japanese
Oral Session

Reinhard Klingel

ProgramSunday, Oct.
20, 2019

Pathogenic Antibodies and Lipoproteins – Current Trends in Therapeutic
Apheresis

PosterPresentation

LS4-01

ProgramFriday, Oct.
18, 2019

Program & Abstracts(Dermatology, Kagoshima University Graduate School of Medical and Dental
Sciences, Kagoshima, Japan)

25

ISFA & JSFA 2019 in KYOTO
GS2-04 JSFA guidelines for hematological disorders
Yasunori Ueda

(Department of Hematology/Oncology, Transfusion and Hemapheresis Center
Kurashiki Central Hospital Okayama, Japan)

GS2-05 JSFA Guidelines 2020 for Neurological Diseases
Kyoichi Nomura(Department of Neurology, Saitama Medical Center, Saitama Medical University, Japan)

GS2-06 Description of new guidelines for therapeutic apheresis in the ﬁeld of rheumatic
disease
Makio Kusaoi(Department of Internal Medicine and Rheumatology, Juntendo University Schoolof Medicine, Tokyo, Japan)

GS2-07 American Society for Apheresis (ASFA) Guidelines for Apheresis
Bruce SachaisNicole Aqui

(New York Blood Center, USA)

Room D

9:00-10:30

Symposium 10 _ LDL

Lowering Lp(a)Chairs: Wolfgang Ramlow
Beate Jaeger
Atsushi Nohara(Apheresis Center Rostock,Germany)(Clinical Genetics, Ishikawa Prefectural Central Hospital, Japan)

SY10-01 Lipoprotein(a)-Risk Marker and Therapeutic Target
Reinhard Klingel

SY10-02 Beate Jaeger(Apheresis Research Institute, Cologne and 1st Department of Internal Medicine,
University of Mainz, Germany)

SY10-03 Antisense and RNA interference drug therapy for the reduction of Lp(a) levels
Patrick M. Moriarty(University of Kansas Medical Center, USA)

SY10-04 Effect of PCSK9i on Lp(a)Atsushi Nohara

10:45-12:15(Clinical Genetics, Ishikawa Prefectural Central Hospital, Japan)

Symposium 11 _ LDL

Position of Lipoprotein Apheresis after Recent Development of Lipid Lowering
Drugs
Chairs: Patrick M. Moriarty(University of Kansas Medical Center Kansas City, KS, USA)
Mariko Harada-Shiba (National Cerebral and Cardiovascular Center Research Institute,Japan)

SY11-01 Treatment of FH in Japan
Hisashi Makino(The Department of Diabetes and Lipid Metabolism, National Cerebral andCardiovascular Center, Osaka, Japan)

SY11-02 Treatment of Familial Hypercholesterolemia in the United States
P. Barton Duell(Oregon Health and Science University Portland, OR, USA)

SY11-03 Characteristics of dyslipidemic high-risk cardiovascular patients and how to
identify them in clinical routine
Wolfgang Ramlow

26(Apheresis Center Rostock, Germany)

SY11-04 Characterization of patients being treated with lipoprotein apheresis (LA) at theDresden LA center

Safety management in CART using pump for the driving force

LS5-02

What is highly effective CART?

15:30-17:00

ProgramSaturday, Oct.
19, 2019

Symposium 12 _ CART/Ascites

CART, Its Current Status and Prospect for the Future Leaps
Chairs: Yuji Kamijo
Norio Hanafusa(Department of Nephrology, Shinshu University School of Medicine,Japan)(Department of Blood Purification, Tokyo Women’s Medical University,
Tokyo, Japan)

SY12-01 Veriﬁcation of serum albumin elevating effect of cell-free and concentrated
ascites reinfusion therapy for ascites patients
Yosuke Yamada(Department of Nephrology, Shinshu University School of Medicine, Nagano, Japan)

SY12-02 Characteristics and methods of the cell-free and concentrated ascites reinfusion
therapy (CART) procedure in Japan(Medical Engineering Center, Medical Hospital of Tokyo Medical and Dental
University, Japan)

State of the Art
in the World

Atsushi Ohkubo

SY12-03 Cell-free and Concentrated Ascites Reinfusion Therapy (CART) against
malignancy-related ascites
Tetsuya Ito

EnglishOral Session(Department of Palliative Care, Japanese Red Cross Medical Center, Tokyo,
Japan)

17:05-18:05

Japanese
Oral Session

SY12-04 Safety and quality control for ﬁltered and concentrated ascites reinfusion
therapy
Taiju Utsugisawa(Department of Transfusion Medicine and Cell Processing, Tokyo Women’s
Medical University, Tokyo, Japan)

Evening Seminar 3
Sponsored by Japan Blood Products Organization

Takafumi Ito (Division of Nephrology, Shimane University Hospital, Japan)

ES3-01

Appropriate diluted albumin solution as replacement ﬂuids in PE and SePE

ES3-02Clinical management of albumin replacement in selective plasma exchangeSponsored
Seminar

Chair:

Guideline
Session

LS5-01

Symposium(Department of Blood Purification, Tokyo Women’s Medical University,
Tokyo, Japan)

Apheresis
Manual Lecture

Norio Hanafusa

Technical Talk

Chair:

ProgramSunday, Oct.
20, 2019

Sponsored by Kaneka Medix Corp.

Special Lecture

Luncheon Seminar 5

E-ISFA
Work Shop

12:30-13:30(Department of Internal Medicine III, University Hospital at the Technische
Universitat Dresden, Germany)

PosterPresentation

Ulrich A. Julius

ProgramFriday, Oct.
18, 2019

Program & Abstracts

27

ISFA & JSFA 2019 in KYOTO
Room B-1

9:00-10:30

Symposium 13 _ Hematology/Transfusion

Hemapheresis and cellular therapy-state of the art and clinical applications-1
Chairs: Yasunori Ueda

(Kurashiki Central Hospital, Japan)

SY13-01 Overview of Cellular Therapy and the Critical Role for Apheresis Professionals
Bruce SachaisNicole Aqui

(New York Blood Center, USA)

SY13-02 Cellular Collections for Immunotherapy, Perspective from a Large Academic
CenterNicole Aqui

(Department of Pathology and Laboratory Medicine, University of Pennsylvania,
Philadelphia, Pennsylvania, USA)

SY13-03 Impact of Growing Leukapheresis Indications: Two Perspectives from a
Hemapheresis Practitioner
Chrissy Anderson(Apheresis Operations, Bluebird Bio, Inc., USA)

SY13-04 Recent advances in diagnosis and treatment of light-chain (AL) amyloidosis
Nobuhiro Tsukada

10:45-12:15(Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan)

Symposium 14 _ Hematology/Transfusion

Hemapheresis and cellular therapy-state of the art and clinical applications-2
Chairs: Yasunori Ueda

(Kurashiki Central Hospital, Japan)

SY14-01 Autotransplantation for POEMS syndrome
Masahiro Takeuchi(Department of Hematology, Chiba University Hospital, Chiba, Japan)

SY14-02 Update on granulocyte transfusions, including granulocytapheresis and clinicaleffectiveness
Satoshi Yoshihara(Department of Transfusion Medicine and Cellular Therapy, Japan)

SY14-03 Plasmapheresis for the treatment of acquired thrombotic thrombocytopenic
purpuraYasunori Ueda

(Department of Hematology / Oncology, Transfusion and Hemapheresis Center
Kurashiki Central Hospital Okayama, Japan)

SY14-04 Atypical hemolytic uremic syndrome
Akira Ashida

12:30-13:30(Department of Pediatrics, Osaka Medical College, Japan)

Luncheon Seminar 6
Sponsored by Recordati Rare Diseases Japan K.K.

Updates on familial hypercholesterolemia (FH) including HoFH
〜Treatment with LDL-Apheresis and MTP Inhibitor〜
Chair:

Mariko Harada-Shiba (National Cerebral and Cardiovascular Center Research Institute,Japan)

28

Kyoko Inagaki

Synergistic effect of Lomitapide and PCSK9 inhibitor on familial
hypercholesterolemia homozygote
Hiromi Tasaki

15:30-17:00

ProgramSunday, Oct.
20, 2019

LS6-02(Division of Diabates, Endocrinology and Metabolism, Department of Medicine,
Nippon Medical School, Japan)(Cardiovascular medicine, JR Kyushu Hospital, Japan)

Symposium 15 _ Nephrology

Apheresis for kidney disease(University of Connecticut, USA)
(Division of Nephrology, Shimane University Hospital, Japan)

Symposium

Chairs: Andre Kaplan
Takafumi Ito

Guideline
Session

SY15-01 Therapeutic Apheresis in the Field of Nephrology - Future Direction andMissions of Nephrologists(Department of Blood Purification, Tokyo Women’s Medical University, Tokyo,
Japan)

Apheresis
Manual Lecture

Norio Hanafusa

SY15-02 Apheresis for nephrotic syndrome
Kengo Furuichi(Department of Nephrology, Kanazawa Medical University, Uchinada, Japan)

Technical Talk

SY15-03 Apheresis for Focal Segmental Glomerulosclerosis
Andre A. Kaplan(University of Connecticut Health Center, Farmington, CT, USA)

E-ISFA
Work Shop

SY15-04 Current status of Apheresis in the practice of Rapidly Progressive
Glomerulonephritis in Japan
Shuzo Kaneko(The department of Nephrology, University of Tsukuba, Ibaraki, Japan)

State of the Art
in the World

SY15-05 Efﬁcacy of selective plasma exchange at pre-transplant desensitization of
ABO-incompatible kidney transplantation
Toshihide Naganuma(Department of Urology, Osaka City University, Osaka, Japan)

English Oral 2 _ Nephrology/others

Eriko Kinugasa

Japanese
Oral Session

Chair:EnglishOral Session

Room B-2

9:00-10:00

ProgramSaturday, Oct.
19, 2019

Treatment efﬁciency of uncontrolled familial hypercholesterolemia withlomitapide and apheresis-

Special Lecture

LS6-01

ProgramFriday, Oct.
18, 2019

Program & Abstracts(Showa University Northern Yokohama Hospital, Japan)

Natavudh Townamchai (Division of Nephrology, Department of Medicine, Chulalongkorn University andPosterPresentation

EO2-02 Clinical outcome of the apheresis therapy for acute antibody-mediated rejection
after kidney transplantation in our instituteSponsored
Seminar

EO2-01 Comparing the Outcomes of Desensitization for ABO Incompatible and HLA
Incompatible Kidney Transplantation
King Chulalongkorn Memorial Hospital, Bangkok, Thailand)

Yasushi Mochizuki(Division of Blood Purification, Nagasaki University Hospital, Japan)

EO2-03 Cost analysis of therapeutic plasma exchange procedure at Middlemore
Hospital, New Zealand
Yvonne YL Lee(Health Economic and Market Access, Terumo BCT Asia, Singapore)

29

ISFA & JSFA 2019 in KYOTO

10:45-12:00
Chair:

Japanese Oral 3 _ Collagen Disease/Rheumatology/others

Takuya Nemoto(Department of Internal Medicine and Rheumatology, Juntendo
University School of Medicine, Japan)

JO3-01 Plasma exchange in 3 patients with antiphospholipid syndrome
JO3-02 Effectiveness of combined therapy of PSL+IVCY+DFPP for skin sclerosis inpatients with diffuse cutaneous systemic scleroderma
JO3-03 Six cases of anti MDA-5 antibody positive clinically amyopathic dermatomyositis
with rapidly progressive interstitial lung disease treated with plasmapheresis
JO3-04 Apheresis for Immune-related adverse events of immune checkpoint inhibitors
JO3-05 In the case of thrombotic microangiopathy treated by simple plasma exchangewith albumin as the replacement solution

14:00-15:30
Chair:English Oral 3 _ Collagen Disease/Rheumatology/others

Makio Kusaoi(Department of Internal Medicine and Rheumatology, Juntendo
University School of Medicine, Japan)

EO3-01 Prognosis of anti-MDA5 antibody positive clinically amyopathic
dermatomyositis treated with plasma exchange; a case series of single center
experience
Satoshi Kumakura(Division of Nephrology, Endocrinology and Vascular Medicine, Tohoku
University, Sendai, Japan)

EO3-02 Case series: Successful treatment of Adult Onset Still’s Disease (AOSD) using
Plasma Exchange
Fumika Homma(Division of Nephrology, Department of Internal Medicine, Teikyo University,
Tokyo, Japan)

EO3-04 The economic impact of centrifugal technique for therapeutic plasma exchange;
public hospital perspective
Yvonne YL Lee(Hematology Department, National Cheng Kung University Hospital, Taiwan)

EO3-05 Effectiveness of Therapeutic Plasma Exchange in the Treatment of Catastrophic
Antiphospholipid Syndrome: A 15-year Retrospective Review
Dobri Kiprov(Department of Medicine, California Pacific Medical Center, San Francisco,California, USA)EO3-06 The efﬁcacy of plasmapheresis for multiple sclerosis and neuromyelitis optica
unresponsive to steroid-pulse therapy and its immunological prognostic markers
Youwei Lin

30(Department of Neurology, National Center Hospital, National Center of
Neurology and Psychiatry, Tokyo, Japan)

Program & Abstracts
ProgramFriday, Oct.
18, 2019
ProgramSaturday, Oct.
19, 2019(Medical Director of the Blood Bank, Seoul National University
Hospital, Korea)

Lingling Yang

ProgramSunday, Oct.
20, 2019

SA4-01 Artiﬁcial liver treatment improves survival in patients with acute-on-chronic
liver failure: A prope(State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The
First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou,
China)

SA4-02 1,5-Anhydroglucitol predicts proliferation of liver parenchymal cells during liver
regeneration
Yalei Zhao

Symposium(State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The
First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou,
Zhejiang, China)

Guideline
SessionSA4-03 Transcriptomics identiﬁes immune-metabolism disorder in development andprogression of hepatitis B virus-related acute-on-chronic liver failure
Jun Li(State Key Laboratory for Diagnosis and Treatment of Infectious Diseases The
First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou,
China)

SA4-04 Aristolochic Acid I induced FLAP/CysLTs/CYLD signaling axis in premalignant
liver tissue
Kunkai Su

Technical Talk

(State Key Laboratory and National Clinical Research Center for Infectious
Diseases, 1st Affiliated Hospital, College of Medicine, Zhejiang University,
Hangzhou, China)

Chair:E-ISFA
Work Shop

Room E

9:00-10:30

Japanese Oral 4 _ Technology 1

Atsushi Ohkubo

Special Lecture

Kyou-Sup Han

Apheresis
Manual Lecture

Chair:

State of the Art 4 _ Hepatology(ME Center, Tokyo Medical and dental University Hopspital, Japan)

EnglishOral Session

JO4-01 Seeking for a possibility of innovative apheresis for reduction in task load ofpatients

State of the Art
in the World

15:30-16:30

Japanese
Oral Session

JO4-02 Changes in granulocyte adhesion of Adacolumn cellulose acetate beads during
GMA treatment
JO4-03 The usefulness of acquiring access with puncture under shunt map andecho
guidance for GMA therapy

PosterPresentation

JO4-04 Study of session time and adsorption efﬁciency in GMA using single needle
methodSponsored
Seminar

JO4-05 The effect of double-ﬁltration plasmapheresis thermo-mode(DFT) on
hemodialysis patients complicated with peripheral artery disease(PAD)
JO4-06 Survey of adverse events and measures for apheresis therapy

31

ISFA & JSFA 2019 in KYOTO

10:45-12:15
Chair:

Japanese Oral 5 _ Technology 2/others

Hitomi Iwamoto(Tenjinkai Social Medical Corporation, Japan)

JO5-01 Relationship between replacement rate of albumin solution/fresh frozen plasma
combination and changes of plasma ﬁbrinogen levels in plasma exchange
JO5-02 Clinical use of a solute kinetics simulation method for double ﬁltration
plasmapheresis
JO5-03 Comparing centrifugal and membrane therapeutic plasma exchange procedures in Japan
JO5-04 A case report of low-density lipoprotein apheresis using centrifugal separationand dextran sulphate adsorption
JO5-05 A comparative study of double ﬁltration plasma exchange and selective plasma
exchange in ABO blood group incompatible kidney transplantation

13:40-15:10
Chair:

Japanese Oral 6 _ Nephrology/Transplantation

Tsukasa Nakamura(Shinmatsudo Central general Hospital, Japan)

JO6-02 A case of thrombotic microangiopathy, successfully treated with plasma
exchange
JO6-03 Complete remission of steroid-resistant minimal-change nephrotic syndrome by
the treatment with a combination of LDL-apheresis and cyclosporin
JO6-04 Comparison study of AcuFil Multi 55X-II dedicated circuit SHG-1.0 ( PS ) andPrismaﬂex HFset ( PAES )JO6-05 Preoperative LDL apheresis in renal transplantation for FSGS
JO6-06 Adverse effects during plasma exchange of donor speciﬁc anti-HLA antibody
positive kidney transplantation in a patient

15:30-17:00
Chair:

Technical Talk 1

Hitomi Iwamoto(Tenjinkai Social Medical Corporation, Japan)

TT1-01 Therapeutic plasma exchange
TT1-02 Therapeutic double ﬁltration plasmapheresis
Room D Foyer

10:30-11:40
Chair:

PP3-0332

Poster Presentation 3 _ Technology

Motoyoshi Sato

(Shinshiro Municipal Hospital, Japan)

Utilization of the newly established dialysis training system using magnetic
particles for apheresis trainingPP3-05

Our experiences with plasm apheresis therapy from 2008 to 2018

PP3-06Long-term results of treatment for critical limb ischemia in maintenance dialysis
patients

PP3-07The Education Method in Apheresis in The Clinical Engineering TechnicalTraining School of Japan(Division of Nephrology, Department of Internal Medicine, Otemae Hospital, Japan)

Efﬁcacy of plasmapheresis for patients with stiff person syndrome. Summary ofcase-study reports
Akihito Tanaka

Symposium
Technical Talk

(Department of Nephrology and Extracorporeal haemocorrection of Medical
Military Academy, St.Petersburg, Russia)

Plasma Exchange to Myopathy without Optic Neuritis or Quadriplegia in
Neuromyelitis Optica Spectrum Disorders: A Case Report
Yoshito Yamaguchi

PP4-05Special Lecture

Treatment of Stiff-person syndrome using double ﬁltration plasmapheresis andimmunoadsorption
Sergei Bardakov

PP4-04(Department of Neurology, Shin Kong WHS Memorial Hospital, Taipei, Taiwan)

Guideline
SessionSuccessful Treatment with Early Plasmapheresis in Secondary Hemophagocytic
Lymphohistiocytosis(HLH) with Cytomegalovirus Infection in Myasthenia Gravis
Kuan-Yu Lin

PP4-03(Mater Cancer Care Centre, Mater Health Services, South Brisbane, Queensland,
Australia)

Apheresis
Manual Lecture

Red cell exchange verse blood transfusion therapy: improving patient outcomes
Samantha Easton

PP4-02(Faculty of Medical Science, Kindai University, Japan)(Division of Nephrology, Nagoya University Hospital, Nagoya, Japan)

A case of relapsing acquired thrombotic thrombocytopenic purpura successfully
treated with simple plasma exchange and rituximab combination therapy

PP4-07

Efﬁcacy of plasmapheresis for autoimmune limbic encephalitis

Sponsored
Seminar

PosterPresentation

Japanese
Oral Session

PP4-06

E-ISFA
Work Shop

PP4-01

Katsuichi Miyamoto

State of the Art
in the World

Chair:

Poster Presentation 4 _ Neurology/Rare disease/Nursing

EnglishOral Session

15:00-16:10

ProgramSaturday, Oct.
19, 2019

Retrospective comparison and examination about difference of collection method
in Autologous Peripheral Blood Stem Cell Collection (APBSCC)

ProgramSunday, Oct.
20, 2019

PP3-04ProgramFriday, Oct.
18, 2019

Program & Abstracts

33

PosterPresentation

Japanese
Oral Session

EnglishOral Session

State of the Art
in the World

E-ISFA
Work Shop

Technical Talk

Apheresis
Manual Lecture

Guideline
SessionSunday, October 20, 2019

Sponsored
Seminar

Symposium

ProgramSpecial Lecture

ProgramSunday, Oct.
20, 2019

ProgramSaturday, Oct.
19, 2019

ProgramFriday, Oct.
18, 2019

ISFA & JSFA 2019 in KYOTO
Oct 20th Room A

9:00-10:30

Symposium 16 _ Vasculitis

Apheresis for various vasculitis
Chairs: Wladimir Szpirt
Shoichi Fujimoto(Rigshospitale, Copenhagen, Denmark)(Faculty of Medicine, University of Miyazaki, Japan)

SY16-01 Therapeutic apheresis for cryoglobulinemic vasculitis in Japan
Yuri Ishizaki(Division of Nephrology, Department of Internal Medicine, University of Miyazaki,
Miyazaki, Japan)

SY16-02 Extracorporeal Treatment Measures in Immune-Complex Small-Vessel
Vasculitides
Andreas Kronbichler(Department of Internal Medicine IV (Nephrology and Hypertension), Medical
University Innsbruck, Austria)

SY16-03 Plasma exchange therapy to reduce mortality in Japanese patients withmicroscopic polyangiitis, particularly diffuse alveolar hemorrhage
Yoshiyuki Abe(Department of Internal Medicine and Rheumatology, Juntendo University, Tokyo, Japan)

SY16-04 Should we still plasma exchange in Vasculitis based on Pexivas results?
Wladimir Szpirt

10:45-12:15(Rigshospitale, Copenhagen, Denmark)Symposium 17 _ LDL

Lipoprotein Apheresis in Kidney Disease
Chairs: Eri Muso
Takashi Wada

(Department of Food and Nutrition, Faculty of Home Economics,
Kyoto Kacho University, Japan)(Department of Nephrology and Laboratory Medicine University,
Japan)

SY17-01 Canceled
SY17-02 Lipoprotein apheresis for kidney disease in adult
Norihiko Sakai(Division of Blood Purification, Kanazawa University Hospital, Kanazawa, Japan)

SY17-03 Lipoprotein apheresis for kidney disease in children in US
Katherine Twombley(Pediatrics, Medical University of South Carolina, USA)SY17-04 Lipoprotein apheresis for kidney disease in children in Japan
Naoto Kaneko

12:30-13:30(Department of Pediatric Nephrology, Tokyo Women’s Medical University, Tokyo, Japan)

Luncheon Seminar 7
Sponsored by NIPROTechnical issues with continuous renal replacement therapy management
Chair:

LS7-01

Yutaka Eguchi

Technical issues with continuous renal replacement therapy management
Kunihiko Kooguchi

36(Department of Critical and Intensive Care Medicine, Shiga Universityof Medical Science Shiga, Japan)(Critical care department, Kyoto City Hospital, Japan)

(Department of Pathology, University of Michigan, USA)
(Lifetime Clinical Immunology, Tokyo Medical and Dental University,
Japan)(Department of Lifetime Clinical Immunology, Graduate School of Medical and
Dental Sciences, Tokyo Medical and Dental University, Japan)

Apheresis
Manual Lecture(Department of Pediatrics, Graduate School of Medical Sciences, Kumamoto
University, Japan)

SY18-04 Therapeutic Plasma Exchange Treatment for Wilson’s Disease in the USA

15:30-16:30
Chair:(Transfusion Medicine, Department of Pathology, University of Michigan, Ann
Arbor, Michigan, USA)

Technical Talk

Chisa Yamada

State of the Art 5 _ State of the Art in the World

Yoshihiro Endo

(Department of Clinical Nursing, Shiga University of Medical Science,
Japan)

SA5-01 Neuro-Apheresis: From stroke to Alzheimer’s Disease
Juergen Graessler(Third Department of Internal Medicine, University Hospital Carl Gustav Carus,
Dresden, Germany)

SA5-02 Long-term lipoprotein apheresis: effects on natriuretic peptides, PCSK9, andimmunological parameters
Juergen Graessler(Department and Outpatient Department of Medicine III, University Hospital at
the Technische Universitaet Dresden, Germany)

SA5-03 A Nationwide Population Based Study of Therapeutic Plasma Exchange for 10
years in Korea
Jae Hyeon Park

(Department of Laboratory Medicine, Seoul National University Hospital, Seoul,
Korea)

SA5-04 The Challenges of Placebo Controlled Clinical Trials in Therapeutic Apheresis(Apheresis Care Group, California Pacific Medical Center, Global Apheresis,
San Francisco, CA, USA)

Sponsored
Seminar

Dobri Kiprov

E-ISFA
Work Shop

Jun Kido

Guideline
Session

SY18-03 Plasma exchange and chelator therapy rescues acute liverfailure in Wilson
disease without liver transplantation: Form our experiences

State of the Art
in the World

Masaaki Mori

Symposium(Department of Pediatrics, Osaka Medical College, Japan)

SY18-02 Plasma exchange therapy for cases refractory to IVIG treatment in Kawasaki
disease in Japan

EnglishOral Session

Akira Ashida

Special Lecture

SY18-01 Hemolytic uremic syndrome in pediatric patientsJapanese
Oral Session

Chairs: Chisa Yamada
Masaaki Mori

ProgramSaturday, Oct.
19, 2019

Applications and Effectiveness of Apheresis Therapy for Severe Conditions inChildren

ProgramSunday, Oct.
20, 2019

Symposium 18 _ Pediatrics

PosterPresentation

13:40-15:10

ProgramFriday, Oct.
18, 2019

Program & Abstracts

37

ISFA & JSFA 2019 in KYOTO
Room D

9:00-10:00
Chair:English Oral 4 _ IBD/Ascites/CART/Technology

Tatsuo Tsukamoto(Department of Nephrology and Dialysis, Kitano Hospital,
Tazuke Kofukai Medical Research Institute, Japan)

EO4-01 Treatment result of the curative effect of GCAP for the intractable UC in our
Hospital (examination about the blood throughput)
Katsuji Otsuka(Kumamoto University Hospital, Japan)

EO4-02 Modiﬁcation of the Dialysate Port of Plasma Separator; A measure against
mix-up of plasma separator with hemoﬁlter (ﬁnal report)
Tatsuo Tsukamoto(Department of Nephrology and Dialysis, Kitano Hospital, Tazuke Kofukai Medical
Research Institute, Japan)

EO4-03 Cell-Free and Concentrated Ascites Reinfusion Therapy against refractory
ascites on various disease
Masahiro Hattori(The Department of Surgery, Sapporo Hokuyu hospital, Sapporo, Japan)

EO4-04 Assessing cost of membrane and centrifugal techniques for therapeutic plasma
exchange in Thailand
Srisawat Nattachai(Nephrology Department, Chulalongkorn University, King Chulalongkorn
Memorial Hospital, Bangkok, Thailand)

10:45-12:15

Symposium 19 _ Canceled

13:40-15:10

Symposium 20 _ Collagen Disease/Rheumatology

Therapeutic apheresis for rheumatic diseases
Chair:Ken Yamaji(Department of Internal Medicine and Rheumatology,
Juntendo University School of Medicine, Japan)

SY20-01 Plasma Exchange and Immunoadsorption in Connective Tissue Diseases
Andreas Kronbichler(Department of Internal Medicine IV (Nephrology and Hypertension), Medical
University Innsbruck, Austria)

SY20-02 Extracorporeal Treatment in Systemic Lupus Erythematosus
Katharina Artinger(Division of Nephrology, Department of Internal Medicine Graz, Austria)

SY20-03 The improvement of severe systemic lupus erythematosus with the combined
Plasmapheresis and immunosuppressive treatment: a cohort review
Sanxi Ai

(The Kidney Division of Peking Union Medical College Hospital, Beijing, China)

SY20-04 Therapeutic apheresis for anti-melanoma differentiation-associated gene
5 antibody-positive inﬂammatory myositis associated rapidly progressiveinterstitial lung disease
Makio Kusaoi(Department of Internal Medicine and Rheumatology, Juntendo University Schoolof Medicine, Tokyo, Japan)

SY20-05 Efﬁcacy of Plasma Exchange and Prognostic Factors in Anti-MDA5 Antibodypositive Dermatomyositis with Interstitial Lung Disease
Ran Nakashima

38(Department of Rheumatology and Clinical Immunology, Graduate School of
Medicine, Kyoto University, Japan)

Program & Abstracts

ProgramSaturday, Oct.
19, 2019

EO5-02 Plasma Exchange in Neuromyelitis Optic Spectrum Disorders
EO5-03 Efﬁcacy of intravenous methylpredonisolon and plasmapheresis in relapsing
MOG-IgG+disease: early institution of plasmapheresis
Satoru Oji(Department of Neurology, Saitama Medical Center, Saitama Medical University,
Japan)

Chair:

Japanese Oral 7 _ Hematology/PAD

Shuichi Ota(Sapporo Hokuyu Hospital, Japan)

Technical Talk

9:00-10:00

Apheresis
Manual Lecture

Room B-1

JO7-01 Analysis of the effect of LDL-A on leg ulcers
JO7-02 Successful plasmaexchange(PE) for ABO-incompatible liver transplantation in a
2-year-old child with peliosis hepatis and myotubular myopathy
JO7-03 A case of Goodpasture syndrome successfully treated with continuous plasma
exchange with dialysis
JO7-04 Peripheral blood stem cell harvest based on the number of CD34 positive cells inperipheral blood

Chair:

State of the Art 6 _Neurology/Dermatology/Critical Care Medicine

Flora Sandra Siami

Japanese
Oral Session

10:45-12:15(Clinical Research, HealthCore NERI,USA)SA6-01 Our Achievement In Establishment Of In-house Neurology Driven Therapeutic
Plasma Exchange (TPE) Infrastructure In A Resource-Limited Public Hospital
In Malaysia
Shirley Lee(Neurology Department, Kuala Lumpur Hospital, Malaysia)

SA6-02 Establishment of South East Asia Regional Neurological Disorders Therapeutic
Plasma Exchange Consortium
Sing Keat Wong

Guideline
SessionSymposium(Nephrology unit of internal medicine department, Hospital Universitario
San Ignacio, Pontificia Universidad Javeriana, Bogota, Colombia)

E-ISFA
Work Shop

Camilo Gonzalez

ProgramSunday, Oct.
20, 2019(Department of Dermatology, Gifu University Graduate School of Medicine, Gifu,
Japan)

State of the Art
in the World

Asumi Fujii

Special Lecture

EO5-01 A case of pustular psoriasis deteriorated during the second pregnancy was
successfully treated with intensive GMA and certolizumab pegol

EnglishOral Session

Katsuichi Miyamoto(Department of Dermatology, Gifu University Graduate School of
Medicine, Japan)(Kindai University Faculty of Medicine, Japan)(Department of Neurology, Kuala Lumpur Hospital, Kuala Lumpur, Malaysia)

39

PosterPresentation

Chairs: Mariko Seishima

ProgramFriday, Oct.
18, 2019

English Oral 5 _ Dermatology/Neurology

Sponsored
Seminar

15:30-16:15

ISFA & JSFA 2019 in KYOTO
SA6-03 MicroRNA and granulocyte and monocyte adsorption apheresis on neutrophilic
skin diseases
Yuko Higashi(Department of Dermatology, Kagoshima University Graduate School of Medical
and Dental Sciences, Kagoshima University, Sakuragaoka, Kagoshima, Japan)

SA6-04 The use of therapeutic plasma exchange in clinical settings: an economic
evaluation in a single institution in China
Yvonne YL Lee(Hematology Department, Longyan First Municipal Hospital, Fujian, China)

SA6-05 Cost savings with centrifugal therapeutic plasma exchange in intensive care unit
VietnamYvonne YL Lee(Intensive Care Unit, Ho Chi Minh City Hospital, Vietnam)

SA6-06 The 5-year Experiences and Outcomes in Plasmapheresis of non-Transplantation
Patients in Limited-Resource Center of Thailand
Wanjak Pongsittisak

13:40-15:10(Renal Division, Department of Medicine, Faculty of Medicine, Vajira Hospital,
Navamindradhiraj University, Bangkok, Thailand)

Symposium 21 _ Hepatology 1

Role of apheresis therapy in liver failure 1
Chairs: Lanjuan Li
Kazuaki Inoue(School of Medicine, Zhejiang University, China)(Gastroenterology, Showa University Fujigaoka Hospital, Japan)

SY21-01 Advancement in Liver Failure and Artiﬁcial Liver
Lanjuan Li(State Key Laboratory for Diagnosis and Treatment of Infectious Diseases,
Zhejiang University, Hanghzou, China)

SY21-02 Extracorporeal Liver Support (ELS) in acute and acute on chronic Liver Failure
Jan Stange(Department of Medicine, University of Rostock, Rostock, Germany)

SY21-03 High-volume ﬁltrate hemodiaﬁltration improves recovery rate from hepatic
encephalopathy in acute liver failure patients
Ryuzo Abe

(Department of Emergency and Critical Care Medicine, Chiba University
Graduate School of Medicine, Chiba, Japan)

SY21-04 Continuous Plasma Exchange with Dialysis for Patient with Acute Liver Failure
Kasumi Satoh

15:30-16:30(Emergency and Critical Care Medicine, Akita University Graduate School of
Medicine, Japan)

Symposium 22 _ Hepatology 2

Role of apheresis therapy in liver failure 2
Chair:

Kazuaki Inoue(Gastroenterology, Showa University Fujigaoka Hospital, Japan)

SY22-01 A referral system and an artiﬁcial liver support system as intensive care forpatients with acute liver failure
Keisuke Kakisaka(Division of Hepatology, Department of Internal Medicine, Iwate Medical
University, Morioka, Japan)

SY22-03 Overview of artiﬁcial liver support in Japan
Kazuaki Inoue

40(Showa University Fujigaoka Hospital Division of Gastroenterology, Japan)

Recent advance in TPE for neurological disorders 1(Fu-Jen Catholic University Hospital, Taiwan)(National Hospital Organization, Nagasaki National Hospital, Japan)(National Center of Neurology and Psychiatry, Japan)

SY23-02 Therapeutic Plasma Exchange in Neurological Disorders

Symposium

Naraporn Prayoonwiwa (Division of Neurology, Department of Medicine, Faculty of Medicine, Siriraj
Hospital Mahidol University, Thailand)

SY23-03 Plasmapheresis in Autoimmune Encephalitis

Chairs: Hou-Chang Chiu
Hidenori Matsuo

Guideline
Session(Fu-Jen Catholic University Hospital, Taiwan)(National Hospital Organization, Nagasaki National Hospital, Japan)

SY24-01 Apheresis treatment to autoimmune disorders in central nervous system:
Therapeutic strategy in relapsing NMOSD and MOG-IgG+disease
Satoru Oji(Department of Neurology, Saitama Medical Center, Saitama Medical University, Japan)

SY24-02 Plasmapheresis in patients with dual diagnosis of myasthenia gravis andneuromyelitis optica spectrum disorder
Jiann-Horng Yeh(Department of Neurology, Shin Kong WHS Memorial Hospital, Taipei, Taiwan)

SY24-03 Apheresis for immune neuropathy: Proper use with IVIG
Katsuichi Miyamoto

Chair:English Oral 6 _ Neoplasm /Cardiology/Nephrology

Japanese
Oral Session

13:40-14:40(Department of Neurology, Kindai University School of Medicine, Osaka, Japan)

Tomoharu Shimizu (Department of Surgery, Shiga University of Medical Science, Japan)

EO6-01 The application of the adsorbent for LAP positive T cells to cancer therapy
Kazuo Teramoto(Dept. of Pathology, Shiga University of Medical Science, Japan)

EO6-02 Immunotherapy employing dendritic cell vaccination for patients with advanced
or relapsed esophageal cancer
Masahiro Ogasawara(Department of Internal Medicine, Sapporo Hokuyu Hospital, Sapporo, Japan)

EO6-03 Apheresis treatment for refractory nephrotic syndrome by focal segmental
glomerulosclerosis; A systematic review of published cases
Tatsuo Tsukamoto

Apheresis
Manual Lecture

Recent advance in TPE for neurological disorders 2

Technical Talk

Symposium 24 _ Neurology 2

E-ISFA
Work Shop

10:45-11:45(Chang Gung Memorial Hospital, Taipei, Taiwan)

State of the Art
in the World

Mei-Yun Cheng

EnglishOral Session

Youwei Lin

Special Lecture

SY23-01 Japan-Plasmapheresis Outcome and Practice Patterns Study (J-POPPS) for
Neurological diseases: A multi-center real world survey(Department of Nephrology and Dialysis, Kitano Hospital, Tazuke Kofukai Medical
Research Institute, Osaka, Japan)

41

PosterPresentation

Chairs: Hou-Chang Chiu
Hidenori Matsuo

Sponsored
Seminar

9:00-10:00

ProgramSunday, Oct.
20, 2019

Room B-2

Symposium 23 _ Neurology 1

ProgramSaturday, Oct.
19, 2019

ProgramFriday, Oct.
18, 2019

Program & Abstracts

ISFA & JSFA 2019 in KYOTO

15:30-16:30

Japanese Oral 8 _ Critical Care Medicine/Pediatrics

Chairs: Hidetoshi Shiga
Akira Ashida(Teikyo University Chiba Medical Center, Japan)(Department of Pediatrics, Osaka Medical College, Japan)

JO8-01 Experience of plasmapheresis in our intensive care unit for 4 years
JO8-02 Study of acute poisoning cases treated with direct hemoperfusion in ICU
JO8-03 Successful treatment with cyclosporine for infant with Kawasaki diseaserefractory to both Inﬂiximab and plasma exchange: a case report
JO8-04 Efﬁcacy and safety of selective plasma exchange in children
Room E

9:00-10:30
Chair:

Technical Talk 2

Atsushi Ohkubo(ME center,Tokyo Medical and dental University Hopspital, Japan)

TT2-03 The safety and efﬁcacy of selective plasma exchange
TT2-04 Immunoadsorption in Japan

10:45-12:15
Chair:

Technical Talk 3

Yoshie Tokui(Tokyo Women’s Medical University Hospital, Japan)

TT3-05 Therapeutic Leukocytapheresis
TT3-06 CART (cell-free and concentrated ascites reinfusion therapy)

13:40-15:10
Chair:

Technical Talk 4

Atsushi Ohkubo(ME center, Tokyo Medical and dental University Hopspital, Japan)

TT4-07 Continuos blood puriﬁcation (CBP) / Endotoxin adsorption therapy
TT4-08 LDL adsorption therapy

15:30-16:15
Chair:

Japanese Oral 9 _ Technology 3

Hitomi Iwamoto(Tenjinkai Social Medical Corporation, Japan)

JO9-01 The oncotic pressure and electrolyte composition in the various albumin
solutions as replacement ﬂuids of plasma exchange
JO9-02 Therapeutic effect of selective plasma exchange in Jichi Medical University
JO9-03 An example in which securing blood access by echo utilization was effective in
CAP therapy

42

(The Department of Nephrology and Extracorporeal haemocorrection of Medical
Military Academy, St.Petersburg, Russia)

Low-density Lipoprotein Apheresis in Patients with Acute Kidney Injury due to
Minimal Change Disease requiring Acute Renal Replacement Therapy
Kohsuke Terada(Department of Nephrology, Nippon Medical School, Tokyo, Japan)

PP5-05

A case of atypical hemolytic uremic syndrome, which steroid pulse therapy andplasma exchange were effective but eculizumab was ineffective

PP5-06

A case in which cryoﬁltration was useful for cryoglobulin angiitis complicatedwith intractable systemic lupus erythematosus

PP5-07

Successful treatment of LDL-A for skin ulcers in a patient with systemic sclerosis

Chair:

PP6-01

Poster Presentation 6 _ Critical Care Medicine

Tomoharu Shimizu (Department of Surgery, Shiga University of Medical Science, Japan)

LPS adsorption with Toxipak columns in treatment of sepsis
Alexey A. Sokolov

ProgramSunday, Oct.
20, 2019
Special Lecture
E-ISFA
Work Shop

15:00-16:00

Symposium

Pleiotropic effects of double ﬁltration plasmapheresis in the prevention of
in-stent restenosis in patients with stable coronary artery disease
Valery V. Tishko

PP5-04(The Department of Nephrology and Extracorporeal haemocorrection of Medical
Military Academy, St.Petersburg, Russia)

Guideline
SessionLong-term Ig apheresis in the treatment of lupus nephritis
Alexey A. Sokolov

PP5-02(Blood Purification Center, Osaka Medical College Hospital, Japan)

Apheresis
Manual Lecture

PP5-01Maki Kagitani(The Department of Anesthesiology and Reanimatology, North-Western State Medical
University named after I.I.Mechnikov, St.Petersburg, Russia)

Three cases of acute pancreatitis due to Hypertriglyceridemia treated with PE
and HD

PP6-05

Blood puriﬁcation in patients with sepsis

PP6-06

Clinical study of pressure difference between membranes and effective period ofuse of membranes with continuous hemodiaﬁltration therapy for sepsis

EnglishOral Session

PP6-04

State of the Art
in the World

Chair:

Poster Presentation 5 _Nephrology/Collagen/Disease/Rheumatology

Sponsored
Seminar

PosterPresentation

Japanese
Oral Session

10:30-11:40

Technical Talk

Room D Foyer

ProgramSaturday, Oct.
19, 2019

ProgramFriday, Oct.
18, 2019

Program & Abstracts

43